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Implant Relieves Chronic Pain, Delivers
Drug Directly to Central Nervous System
The Ommaya reservoir, a device surgically implanted in the
head to deliver morphine directly to the central nervous system,
has provided pain relief for 26 cancer patients to date at UT
MDAH. In contrast to oral and parenteral methods of drug
administration, the Ommaya reservoir method requires small
doses of morphine, thus causing few side effects.
According to C. Stratton Hill, MD, Department of Internal Medi
cine, director of the Pain Clinic, the reservoir had been used
solely as a chemotherapy tool until about 3 years ago. At this
time, a study at UT MDAH proved the reservoir also useful in
relieving chronic pain in patients with tissue damage from tumors.
The study, involving 6 patients, found that morphine administered
by means of the reservoir, intrathecally through the lower back or
intraventricularly through the right frontal region of the head, was
highly effective. A small dose (2.5 mg to 4.0 mg) of specially
processed, preservative-free morphine gave 80% to 100% pain
relief within an hour of the injection. Relief continued for up to 24
hours without signs of lethargy or sedation.
Since 1980, Dr. Hill and his associates have successfully used
the Ommaya reservoir in 20 patients. This experience has
revealed more about the workings of the reservoir and the type of
patient most likely to benefit from the device.
The Ommaya reservoir provides direct access to the central
nervous system; this is the key to the reservoir's success. Any
narcotic administered by standard methods must cross the blood
brain barrier to reach the central nervous system and cerebro
spinal fluid, which saturates opiate receptor sites in the brain and

The Ommaya reservoir (center), 3.4 cm in
diameter, is attached to a catheter 7.5 cm
long. When placed in the head (using the
removable metal stylette), the device delivers
morphine directly to the central nervous sys
tem. The inverted U-shaped incision fine
(left), drawn on the patient's scalp over the
medial aspect of the right coronal suture,
outlines the placement site of the reservoir.
The line drawn on the right side of the head
marks the catheter extension from the cal
varium to the floor of the lateral ventricle. A
postoperative right lateral x-ray of the head
(right) illustrates the burr hole drilled through
the right coronal suture (top arrow) and the
catheter tip near the floor of the lateral ventri
cle (bottom arrow).

spinal chord. These sites are believed to be areas concerned with
processing nociceptive stimuli. To cross the blood-brain barrier,
and to compensate for biotransformation of the drug as it
circulates in the body, the dose administered orally or parenterally
must be large (60 mg or more in most cases). The Ommaya
reservoir eliminates these problems and the need for a large
dose. "With the reservoir, the morphine goes straight to the site of
the receptors," Dr. Hill explained.
For this same reason, the side effects of lethargy and sedation,
resulting from large doses required with the other methods of
drug administration, are ameliorated. Dr. Hill theorizes that the
low dose and immediate binding to the opiate receptors prevent
the drug from binding to other cells in the body. "We use such a
low dose that there is not much left after the drug binds to the
receptors; what is left cannot pass through the blood-brain barrier
into the body very easily."
Insertion of the Ommaya reservoir is a simple operation
requiring the patient to receive a local anesthetic. The reservoir is
now only inserted in the head, a more convenient location than
the spine for drug injection. Made of Silastic, the reservoir has a
3.4-cm diameter and is attached to a Silastic catheter 7.25 cm
long. To implant the reservoir, the neurosurgeon makes a U
shaped incision on the scalp in the right frontal region of the head
and pulls the scalp flap back. The incision is slightly larger than
the diameter of the reservoir. A circle of pericranium the size of
the reservoir is excised and a burr hole drilled through the right
Continued on page 2

Ommaya Reservoir . . .
Continued from page 1
coronal suture. The dura is then opened to allow visualization of
the frontal cortex. A needle is inserted through the burr hole to the
horn of the ventricle, and air is injected into the ventricle to
delineate it. After the needle is removed, the catheter, attached to
the reservoir, is passed along the same path so that the catheter
tip reaches the roof of the ventricle and penetrates it. The
catheter is further advanced until the reservoir rests on the
calvarium.
The position of the catheter tip is checked with a lateral skull
x-ray. If the reservoir is properly placed, the surgeon sutures the
reservoir to the pericranium on the outside of the calvarium and
pulls the flap of scalp over the reservoir. Cerebrospinal fluid from
the ventricle enters the reservoir. The reservoir may be used 48
hours after the operation and is generally filled every 8 to 12
hours thereafter depending on the patient. A patient's relative or
friend can learn to fill the reservoir with a simple injection through
the scalp flap. The patient and those administering the drug also
learn aseptic techniques in caring for the injection site.
Although the Ommaya reservoir has displayed good results,
there are some limits to its application. Experience has shown
that the reservoir is most effective for alleviating pain associated
with tissue damage by a tumor. In addition, because of the slight
risks of surgery, the reservoir is recommended only for those
patients who are responding poorly to morphine administered
orally or parenterally, have strong family or friend support, and
have an expected longevity of at least a month. The Ommaya
reservoir can offer a solution to a wide range of problems facing a
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New Book Published
The 1982 Year Book of Cancer, 26th in a series of timely
briefings representing a broad spectrum of oncologic literature, is
now available (Year Book Medical Publishers, Inc., Chicago,
1982, 477 pages, $39.95). Edited by R. Lee Clark, MD, Russell
W. Cumley, PhD, and Robert C. Hickey, MD, this volume contains
271 article abstracts, representing approximately 100 journals.
Chosen from the oncologic literature of the past year, the
contents reflect a number of trends, including: Cancer etiology
and prevention; the use of computerized axial tomography for
cancer diagnosis, staging, therapy planning, and follow-up; the
development of new surgical techniques; and advances in the
field of immunology.

patient with this profile, providing pain relief, freedom to leave the
hospital, and, in some cases, economic relief, as well.
The device can be used for extended periods, Dr Hill said,
citing the example of a young woman who has used the reservoir
for more than a year without complications. Although morphine
injected through the reservoir may cause some nausea 30
minutes to an hour after the injection and constipation, there has
been no evidence of respiratory depression. Most patients using
the Ommaya reservoir have limited life expectancies; complete
pain relief and reduction of side effects allow them to lead
relatively normal lives.
Illustrating the benefits of the reservoir, Dr Hill related the story
of a woman suffering severe pain from carcinoma of the cervix.
"When it became clear that the disease was progressing and the
patient was not responding to treatment, she asked to spend her
last days at home in another city," he explained. But two
problems stood in the way: She was receiving continuous
infusions of morphine with an infusion pump, which required
hospitalization, and her insurance would cover the cost of the
infusion (up to $150 a day) only if she were in a hospital or
extended-care facility in the Houston area.
She was a good candidate for the ·ommaya reserVoir and
decided to undergo the operation. "We cut her morphine dose to
a hundredth of what she had been getting, " Dr Hill said. Pain
relief with the infusion pump necessitated administration of 1800
mg of morphine each day; with the Ommaya reservoi r, relief was
accomplished with only 18 mg each day (9 mg injected every 12
hours). Use of the reservoir reduced expenses to a nominal level.
Because her husband was able to give the injections, the patient
was no longer dependent on the infusion pump and was able to
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When she died 2 months later, she was receiving 27 mg of
Communication
morphine every day; as often happens, she had developed a
tolerance to the drug. However, Dr Hill explained, the Ommaya
reservoir freed her to enjoy her last weeks at home, alert, and
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New Drug Combination Improves Survival For
Patients with Metastatic Prostate Cancer
by Christopher J. Logothetis, MD, Department of Internal Medicine, Melvin L. Samuels, MD, Department of Internal Medicine,
Andrew C. von Eschenbach, MD, Department of Urology,
Antonio Trindade, MD,* Sheryl Ogden, BSN, Department of
Internal Medicine, Cindy Grant, BS,* and Douglas E. Johnson,
MD, Department of Urology

This article is a summary of a paper that first appeared in Journal
of Clinical Oncology 1 (6):368-379, June 1983.
According to American Cancer Society estimates, 23,000 men
died last year in the United States of prostatic cancer, the second
most common malignancy in men after lung cancer. Infrequent
early diagnosis accounts for this high mortality; almost half (45%)
of all patients have metastatic disease at diagnosis, and of these
only 20% survive 5 years.
Because many patients have metastatic disease refractory to
standard hormone therapy, various chemotherapeutic agents
have been investigated. We have found the combination of
doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) to yield a
higher objective response rate in these patients than other singleand combination-drug regimens investigated to date.
The different response criteria used in various drug studies and
the clinical heterogeneity of disseminated prostate cancer have
complicated the comparison of different drug regimens. For this
reason, our study was planned not only to test the effectiveness
of DMF chemotherapy, but also to devise a standard staging
system and response criteria for patients with hormone-refractory
metastatic prostate cancer.

Methods
Sixty-two patients were treated with DMF chemotherapy between December 1979 and October 1981. The median age of the
study population was 63.5 years.
All patients had histologically verified adenocarcinoma of the
prostate, the cell type found in 95% of all prostatic malignancies.
Excluded from the study were patients with transitional cell
carcinomas of the prostatic ducts. The patients were considered
to be hormone refractory if, in addition to subjective deterioration
after hormone therapy, they demonstrated progressive disease
by bone scan, rising serum acid phosphatase or alkaline phosphatase, or the development of new metastases. Patients were
not excluded from the study because of an expected poor
survival or poor performance status. Exclusion criteria included
the presence of overt congestive heart failure and bone marrow
failure attributed to radiation therapy. Patients who had received
prior chemotherapy were also excluded.
Forty-eight patients (77.4%) received radiation therapy prior to
initiation of chemotherapy: 26 (41.9%) had radiation therapy to
the pelvis only, whereas 22 (35.5%) had radiation to the pelvis
and extrapelvic sites. All patients received hormone therapy prior
* No longer at UT MDAH.
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Bone scans of a patient with stage
(Osseous 1) metastatic
prostate cancer at initiation of OM F chemotherapy (left) and a
year later (right) provide evidence of skeletal disease regression
after treatment.
to chemotherapy: 49 were treated with diethylstilbestrol and
orchiectomy, 11 with diethylstilbestrol alone, and 2 with chlorotrianisene.
Clinical evaluation included a complete history and physical
examination, bone scan, bone·survey, chest x-ray, intravenous
pyelogram, electrocardiogram, cardiac scan, serum acid phosphatase, serum alkaline phosphatase, SMA-12, and complete
hemogram. Computerized tomography of the abdomen and
pelvis and lymphangiography were performed on selected patients.
The treatment regimen consisted of DMF delivered intravenously to outpatients. The first 22 patients received doxorubicin,
50 mg/m2 of body surface area, on day 1 of each course, 5fluorouracil, 750 mg/m 2 on days 1 and 2 of each course, and
mitomycin-C, 10 mg/m 2 on day 1 of each course. By dividing the
dose of doxorubicin and mitomycin-C on two subsequent days
(doxorubicin, 25 mg/m 2 days 1 and 2; mitomycin-C, 5 mg/m 2 on
days 1 and 2), emesis was significantly ameliorated. This
modification was adopted for the last 40 patients studied.
The three-drug combination was delivered at increasing intervals between courses; the duration of each interval was determined by marrow recovery. In the absence of marrow recovery
due to tumor infiltration, a granulocyte count of more than
2,000/mm 3 and a platelet count of more than 100,000/mm3 was
required prior to administration of a subsequent course of
chemotherapy. Although we had initially planned not to decrease
the drug dose, 3 patients required a 20% dose reduction because
of persistent thrombocytopenia. The 12 patients with central
nervous system involvement received 2,500 rad to the single
most threatened central nervous system site simultaneously with
Continued on page 6
3

Leukocyte Interferon Inhibits Growth
by Helmuth Goepfert, MD, Department of Head and Neck
Surgery, Jordan U. Gutterman, MD, Department of Clinical
Immunology and Biologic Therapy, William J. Dichtel, MD,* Roy
B. Sessions, MD, t Ayten Cangir, MD, Department of Pediatrics,
and Marcelle Sulek, MOt
This article is a summary of a paper that first appeared in Annals
of Otology, Rhinology & Laryngology 91:431-436, July-August
1982.

Juvenile laryngeal papillomatosis is the most common benign
proliferative condition in the larynx of children. Also found in less
aggressive forms in adolescents and adults, laryngeal papillomas
have a relentless propensity for recurrence and a befuddling lack
of behavioral predictability. For this reason, standard surgical
treatment is often only temporarily successful, and repeated
surgery is usually required.
Alternative treatments, such as cryosurgery, diathermy, ultrasonography, radiotherapy, steroid hormones, cytotoxic drugs,
biologic response modifiers, and CO2 laser vaporization (the
most popular recent method) have been investigated. The
general philosophy of management using these methods has
been to control the growth of the papillomas with minimum
danger to normal tissues in the hope that the aggressiveness of
the tumor will diminish in time. In line with this philosophy, UT
MDAH in collaboration with Baylor College of Medicine conducted a study of interferon (IFN) for this disease. The results
indicated that IFN may be one of the most effective and least
toxic treatments for this virally related tumor.
It is assumed that juvenile laryngeal papillomatosis is induced
by a papilloma virus, a subgroup of the papova viridae family.
Papilloma viruses are both host- and tissue-specific; they induce
epithelial and fibroepithelial tumors in skin and mucosa! epithelia
and are thought to be responsible for cutaneous lesions as well
as mucosal papillomas, such as laryngeal and anal-genital warts.
Interferon was chosen as treatment for juvenile laryngeal
papillomatosis because of its antiviral, antiproliferative, and
immunomodulating effects, clearly demonstrated with myxovirus
and herpes simplex virus. By itself, IFN has no direct antiviral
action; however, it does induce synthesis of intracellular enzymes
that act to control viral growth. Patients in this study were treated
with human leukocyte (alpha) IFN, a type of IFN induced by
viruses and used in most clinical trials.

Methods
Fourteen patients with aggressive laryngeal or laryngotracheobronchial papillomatosis were included in the study (Table 1). Ten
patients were male, and 4 were female. There were 4 adults, 2
adolescents, and 8 children (less than 10 years old); ages ranged
*No longer at UT MDAH.
tFormer1y of the Department of Otolaryngology, Baylor College of Medicine, Houston,
Texas.
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from 2 to 35 years. All patients were white. Three patients had
papillomas in all three possible areas: Larynx, trachea, and
bronchi. The adult patients had required two or more therapeutic
endoscopies within the preceding year, and all children had four
or more such procedures during that time. All patients had
undergone numerous endoscopies previously; 2 patients had
had more than 60 procedures, and 1 patient had over 300
endoscopies in his lifetime. Eight patients had previously required
or were currently dependent on tracheostomy. Six patients had
had major crises during their illnesses, such as acute airway
obstruction or cardiopulmonary arrest.
Before the patients were admitted to the study, detailed
histories were taken, and physical examinations were performed.
Complete blood counts, platelet counts, liver function studies,
serum urea nitrogen levels, creatinine determinations, and chest
roentgenograms were obtained. Direct laryngoscopy and appropriate laser vaporization were performed on all patients prior to
initiation of IFN treatment. Patients underwent monthly laryngoscopies during the first 3 months of treatment and at 2- to 3month intervals thereafter, as dictated by clinical progress.
Eleven of the 14 patients underwent laryngoscopies by the same
surgeon. The extent and distribution of papillomas were recorded
diagrammatically in each case.
During each patient's treatment, complete blood differential
and platelet counts were obtained weekly for the first month of
treatment, twice a month during the second, and monthly during
the remainder of the period of IFN administration. Liver and renal
function studies were performed monthly for the first 3 months of
treatment and subsequently on a bimonthly basis.
Alpha IFN was obtained from the Finnish Red Cross and Blood
Transfusion Laboratories, Helsinki, Finland. The initial daily dose
of IFN was 2 million units/m 2 of body surface area administered
intramuscularly. The frequency of administration was changed to
three times weekly whenever the papilloma growth rate decreased or remained stable over two successive endoscopies.
Furthermore, dose reduction (to 1 million units/m2 ) or changes in
frequency of dose administration were called for whenever the
white blood cell (WBC) count dropped below 2500/cu mm or the
level of serum glutamic oxaloacetic transaminase (SGOT) rose
above 100 units/ml. If toxicity persisted despite dosage changes,
IFN was temporarily discontinued until blood test values returned
to normal. Withdrawal of the patients from IFN therapy was
considered on an individual basis.
Response to treatment was determined by evaluation of the
diagrammatic representation of disease recorded at the time of
each endoscopy. Categories of response were: Complete response, no evidence of papillomas present in the laryngotracheobronchial area; good response, an estimated 75% reduction of
the overall papilloma volume; moderate response, 50 to 75%
estimated reduction; and slight response, 25 to 50% reduction.
Any reduction in papilloma size was assumed to represent a
response to IFN. If no discernible reduction in growth occurred or
if growth increased, it was considered a negative response.
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Of Virally Related Laryngeal Tumor
TABLE 1. Summary of Characteristics of Patient Population*

Patient

Sex

Age
(yr)

Onset
Age
(yr)

Location

Crisist

IFN Treatment

Papilloma Natural History
Endos

Months

Toxicity

Initial
Response

Sustained
Response

1

M

3

1.5

Larynx

Yes

Many

7

Slight-liver

Slight

Yes

2

M

35

32

Larynx

No

Many

11

Slight-liver,
WBC

Complete

Yes

3

M

3

1.5

Larynx/trachea
(tracheostomy)

No

Many

11

Slight-liver,
WBC

Complete

Yes

4

M

9

6

Larynx

No

Many

6

Markedliver, WBC

None

5

M

30

25

Larynx
(tracheostomy)

Yes

Many

10

None

Complete

No-grew
at 7 mo

6

F

5

3

Larynx

No

Many

7

Markedliver

Complete

LTF at
8 mo

7

F

2

1

Larynx, TBP
(tracheostomy)

Yes

Many

12*

None

Moderate

No-grew
at 6 mo

8

M

26

2

Larynx
(tracheostomy)

No

60+

11

None

Complete

No-grew
at 4 mo

9

M

27

2

Larynx
(tracheostomy)

No

300+

9

None

Good

Yes

10

M

12

5

Larynx

Yes

60+

12

Moderateliver, WBC

Good

No

11

F

8

5

Larynx
(tracheostomy)

Yes

Many

11

Moderateliver, WBC

Good

No-grew
at 4 mo

12

M

14

4

Larynx, TBP
(tracheostomy)

No

Many

7

Slight-WBC

Slight

Yes

13

M

4

2

Larynx, TBP
(tracheostomy)

Yes

Many

12

None

Moderate

Yes

Larynx

No

Many

4

Markedliver

Slight

No

14

F

f

8

-

-

• Abbreviations are as follows: IFN = Interferon; WBC = White blood cell; TBP = Tracheobronchial pulmonary involvement; LTF = Lost to follow-up.

t History of either respiratory obstruction necessitating tracheostomy or cardiorespiratory arrest.
*Continuing.

Results
Twelve of the 14 patients completed a minimum of 7 months of
IFN therapy. Patient 4 was removed from the study because of
continued toxicity (primarily SGOTelevation) despite dose modifications. Patient 14 was removed from the study at parental
request after the first signs of significant liver toxicity. These
patients had shown no response or slight response while
receiving the drug.
The responses were distributed as follows among the 12
evaluable patients: 5, complete response (2 having sustained
responses); 3, good response (1 sustained); 2, moderate response (1 sustained); and 2, slight response (2 sustained).
Of the 5 patients with complete response, there were 3 adults
and 2 children (3 and 5 years old). All the adults showed
complete or good response. The 2 patients in whom slight
responses were seen were 3 and 14 years of age. Six of the 12
patients who responded sustained the initial response throughout
the entire period of IFN administration. The remaining 6 responding patients failed to sustain the initial tumor response. There was
no apparent correlation between the degree of initial response
and its duration.
Nine patients were evaluated while receiving the drug for
periods longer than 7 months: 3 patients for 12 months; 4 patients
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for 11 months; 1 patient for 10 months; and 1 patient for 9 months.
Nine patients have had follow-up examinations at least 1 month
after cessation of IFN treatment. Two of these patients (1 and 12)
had slight increases in growth since IFN withdrawal. Two other
patients (9 and 11) had marked and moderate increases in
growth, respectively. Patient 13 showed a transient diminution of
disease for approximately 1 month after cessation of treatment
followed by renewed growth of papillomas. Patients 2, 3, 5, and 6
have been followed for 1 to 3 months without any signs of
increased growth. Patients 2 and 3 remain free of disease.
Toxicity was evaluated in all 14 patients initially entered in the
study. Of the 9 patients who demonstrated signs of toxicity, 3
showed complete responses, 2 had good responses, 3 had slight
responses, and 1 had no response. Neither of the 2 patients with
moderate responses demonstrated any toxicity.
Temperature elevation was common during the first few
injections of IFN but did not appear after the patients had
received multiple doses. Malaise, fatigue, and slight anorexia
were not ignored but were usually thought to be of minor
significance. As a matter of fact, the infants who showed marked
regression of tumor usually became more active and had
increased appetites. Opportunistic infections did not occur.
White blood cell drop (below 2500/cu mm) and elevation in the

Continued on page 8
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Prostate Cancer .
Continued from page 3

the first course of chemotherapy.
To compare response to treatment of subgroups of patients, we
adopted a unique clinical and prognostic staging system. The
staging system employed four clinical categories: Osseous I (0,),
axial skeletal involvement; Osseous II (011), axial skeletal plus
diaphyseal and distal extremity involvement; Visceral I (V,),
parenchymal lung metastasis; Visceral II (Vu), visceral involvement, other than lung (usually liver, brain, or mediastinum).
Patients who otherwise would be classified in the O, or V,
category but had bone marrow failure attributed to tumor infiltration of the marrow cavity or renal failure (serum creatinine > 2 mg/di) were placed in their respective stage II categories (0 11 , V 11 ). Nodal metastases were thought to be present in
all patients prior to involvement of the skeleton or viscera and,
therefore, were not considered in the staging system unless the
mediastinum was involved. Patients who had osseous metastases and mediastinal disease were placed in the Vu category.
Although we encountered no patients with nodal metastases as
the only manifestation of recurrent hormone-refractory prostate
cancer, such patients would be included in the 0 1 category.
The response criteria employed throughout the study required
an improvement in all parameters used. To be considered
responders, the patients had to have a 50% reduction in their
elevated serum alkaline phosphatase level or acid phosphatase
level on three separate occasions. Patients with abnormal bone
scans were required to show an improvement in bone scan
results. If visceral metastases were present, greater than 50%
reduction in the sum of the perpendicular diameters of each
lesion was required; if lytic metastases were present, blastic
healing was required. No clinical deterioration attributable to
tumor growth or new metastatic sites could develop. Responses
were initially assessed after completion of the second course of
chemotherapy. Patients who received radiation therapy simultaneously with the first course of chemotherapy had to show
improvement in sites other than the irradiated site to be considered responders. A complete response required the total
resolution of all initially abnormal laboratory, radiographic, and
bone scan findings. The duration of response was calculated for
patients in each of the clinical categories of disease and for the
total population.

Results
Of the 62 patients, 30 (48%) met the criteria for an objective
response to chemotherapy. Responses were obtained in 12 of 23
patients (52%) with 0 1 disease, 6 of 18 (33%) with 0 11 disease, 8
of 9 (88%) with V, disease, and 4 of 12 (33%) with V11 disease.
Patients with V, disease had a significantly better response rate
(P<0.02) than those with 0 11 or Vu disease.
Kaplan-Meier survival plots were generated comparing responders and nonresponders in the total population. Survival times
were calculated from the day of initiation of chemotherapy. A
significant survival benefit was demonstrated for responding
patients (Wilcoxon signed-rank test, P = 0.001). The median
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The University of Texas
M. D. Anderson Hospital and Tumor Institute
at Houston
37th Annual Symposium
On Fundamental Cancer Research

Mediators in Cell Growth
and Differentiation
March &-9, 1984
Westin Galleria Hotel
Houston, Texas
Cochairpersons: Richard J. Ford, Jr, MD, PhD, Department of Pathology, and Abby L. Maize!, MD, PhD, Department of Pathology
For registration information, write or call the Office of
Conference Services, HMB Box 131, The University of
Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.

survival of the responding patients was 47.5 weeks, while the
nonresponding patients survived a median of 23.8 weeks.
No patient achieved a complete remission. Of the 8 responding
patients with v, disease, 2 had complete resolution of pulmonary
metastases, but because bone scans failed to normalize, they
were not considered to have had complete remission. Among the
30 responding patients, bone scan improvement was marked in
17, while the remaining responders had distinct but less striking
objective improvement.
The duration of response was highest among patients with
osseous metastases. The median duration of response was 11
months for patients with 0 1 disease, 9.5 months for those with 011
disease, 6.5 months for patients having V, disease, and 5 months
for those with V11 disease. The mean response duration for the
total population was 8. 73 months with a range of 3 to 19 months
and a median of 7.5 months. Many of the responding patients
continued to respond; therefore, the response duration would be
expected to increase with a longer follow-up.
Kaplan-Meier survival plots were made comparing the survival
of all patients in each of the four clinical stages. The median
survival was 54.5 weeks for patients with O, disease, 26 weeks
for those with 0 11 disease, 33.8 weeks for patients with V,
disease, and 26 weeks for those with Vu disease. Patients with O,
disease survived significantly longer than the other patients
(Wilcoxon signed-rank test, P = 0.001). No differences were
found in the mean or median ages of patients in each of the
clinical categories. The presence of central nervous system
involvement in 12 patients did not adversely influence survival.
October-December 1983
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The majority of patients suffered nausea and vomiting from at
least one course of chemotherapy. Despite this, the regimen was
well tolerated by outpatients. Stomatitis was unusual. Alopecia
was universal. Common complaints were asthenia and anorexia.
Myelosuppression occurred in 15 patients (24%). Of these, 6
patients required platelet transfusions, and each of these patients
had bone marrow failure due to tumor or radiation therapy.
Despite the advanced age of this population and frequently
associated cardiovascular disease, only 1 patient developed
doxorubicin cardiomyopathy. No patient suffered the reported
hemolytic uremic syndrome attributed to mitomycin-C. One
patient was suspected of having suffered the idiosyncratic
interstitial pneumonia due to mitomycin-C. Three patients suffered fatal complications: One from a pseudomonas sepsis, a
second from an interstitial pneumonia clinically thought to be
induced by a virus or mitomycin-C, and a third from disseminated
varicella.

Discussion
The high objective response rate among patients treated with
DMF who met accepted criteria for tumor measurement contrasts
to the paucity of objective responses reported with other regimens. Among patients treated in the National Prostate Cancer
Project trials, the overwhelming majority of responding patients
were those achieving stabilization. The combination of 5-fluorouracil, doxorubicin, and cyclophosphamide was investigated in
another study in 21 patients; 5 (29%) achieved a subjective
response, and 1 showed improvement in bone scan; no mention
of response in patients with visceral metastases was made. The
combination of doxorubicin and cyclophosphamide, in another
study, failed to achieve an objective response in 3 patients with
abnormal chest x-rays. In an additional study, none of 4 patients
with lytic metastases treated with the combination of melphalan,
methotrexate, prednisone, vincristine, and 5-fluorouracil demonstrated blastic healing; however, 4 of 5 patients presenting with
lytic metastases in our study achieved blastic healing with DMF
chemotherapy.
An integral part of treatment in our study was the use of
radiation therapy in conjunction with DMF chemotherapy for
patients with neurologically threatening lesions. Neurologic complications are frequent in prostate cancer. Most neurologic
complications are caused by local extension of osseous metastases resulting in central nervous system compromise. Osseous
metastases often respond sluggishly to chemotherapy; therefore,

durable responses than patients with visceral metastases, V, and
Vu; patients with 0 1 disease often had an indolent course even in
the absence of a chemotherapy response; and patients with 011,
Vi, Vu disease who failed to respond to chemotherapy rapidly
succumbed to their disease. No significant survival differences
were seen among patients with 011, v,, and V 11 disease, even
though patients with V1 disease had a higher response rate and
those with 0 11 disease a more durable response.
These differences among subpopulations should have important clinical implications if confirmed in a larger population. Such
confirmation will require the development of new chemotherapy
strategies tailored to the needs of each clinical category of
metastatic prostate cancer.
(Physicians desiring additional information should write or call
Christopher J. Logothetis, MD, Department of Internal Medicine,
MDAH Box 77, The University of Texas M. D. Anderson Hospital
and Tumor Institute at Houston, 6723 Bertner Avenue, Houston,
Texas 77030, (713) 792-2830.-ED)
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the simultaneous use of radiation therapy with the first course of
This conference is designed for hospital administrators
chemotherapy is essential to the aggressive management of
and directors of nursing and pharmacy to answer adminisneurologically th reatened patients.
trative questions regarding cancer chemotherapy. Areas to
We believe DMF chemotherapy is effective in the treatment of
be discussed include legal and medical risks associated
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- + - -erate toxicity, achieved a 48% objective response rate and
chemotherapeutic agents, and the handling of chemopalliated pain. These results were obtained with a study populatherapeutic agents.
tion at high risk for toxicity due to heavy prior radiation therapy
and advanced disease at presentation.
For registration information, write or call the Office of
The staging system and response criteria used identified
Conference Services, HMB Box 131, The University of
subpopulations of patients and allowed for simple and accurate
Texas M. D. Anderson Hospital and Tumor Institute at
comparison of data related to these subpopulations: Patients with
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
only axial skeletal metastases, O,, survived significantly longer
(713) 792-2222.
than those in the remaining three clinical stages (P = 0.001);
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patients with osseous metastases, O, and 0 11 , achieved more
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Leukocyte Interferon .
Continued from page 5
SGOT level (above 40 units/ml) indicated a toxic reaction. Two of
the 9 patients with toxicity were taken off the study because of
persistent side effects. In the remaining 7 patients, depression of
the WBC or elevation of the liver enzyme was totally reversed by
alteration of IFN dose or cessation of the drug altogether.
No correlation between response and the susceptibility of the
patient to IFN toxicity was seen. It is noticeable, though, that of
the 8 patients who were under 1O years of age, 6 demonstrated
SGOT elevations, and 3 of these 6 patients had myelosuppression as well. Only 1 of the 4 adult patients showed mild liver
enzyme elevation and a slight bone marrow suppression. From
these numbers, it appears that age of the patients is an important
factor in tolerance to IFN.

Discussion
Not only are there variations in the natural history of juvenile
laryngeal papillomatosis from patient to patient, but in time
different patterns of aggressiveness may be seen in the same
patient. Several internal and external influences on the host,
some of which escape our present knowledge, induce variations
in the behavior of this benign tumor and add to the difficulty of
treating the disease. More aggressive forms of the disease in the
larynx, which is the site of most frequent involvement, or over the
mucosa of the trachea and bronchi have necessitated the use of
a variety of treatments other than surgical ablation. Interferon,
with its antiviral and immunomodulating effects, was hoped to be
especially effective in treating this proliferative, virally related
tumor.
By study design, it was required that all of our patients have
aggressive papillomatosis; this may have had some influence on
response to IFN treatment. Most patients in our study continued
to receive IFN for more than 9 months without a substantial
increase in the response rate. By and large, the beneficial effects
of the drug were noticed within 6 to 12 weeks of initiation of
therapy.
For accurate determination of response, careful documentation
of disease within the larynx and the tracheobronchial tree is
mandatory. Photographic records of the laryngoscopic findings
will only reflect the superficial and more proximal appearance of
8
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the papillomas and certainly will fall short of any tumor volume
determination. Graphic-pictorial documentation used in this study
depends on the accuracy of the observer. We believe that our
having one endoscopist perform follow-up studies on the majority
of the patients and graphically document results provided the
most accurate, objective evaluation.
In our study we used the IFN preparation originally developed
by Cantell of the Finnish Red Cross Blood Transfusion Center
and the Central Public Health Laboratory in Helsinki. The
preparation's purity is approximately 1%. Lymphoblastoid IFN
and IFN obtained through the recombinant DNA technology are
of 80-95% purity, respectively. Furthermore, it has been shown
that the alpha IFN obtained by the Cantell method is probably a
mixture of several subtypes of IFN, each one with a specific
activity.
Our data suggest that the relatively impure preparations of
alpha IFN used here can lead to the regression of papillomas. We
are hopeful that further studies of more pure forms of IFN for
patients with laryngeal papillomas of a variety of clinical presentations will yield even better results.
(Physicians desiring additional information should write or call
Helmuth Goepfert, MD, Department of Head and Neck Surgery,
MDAH Box 69, The University of Texas M. D. Anderson Hospital
and Tumor Institute at Houston, 6723 Bertner Avenue, Houston,
Texas 77030, (713) 792-6920.-ED)

Question/Answer
Q: What is the value of the occult blood test in cancer

detection?

A: The stool guaiac slide test (occult blood test) is an easy,
painless, and inexpensive test to detect the presence of occult
blood in the stool, a common sign of colorectal cancer.
In patients with early disease, occult blood in the stool often
may be the only sign or symptom present. This fact may account
for the less than 50% detection rate for early localized colorectal
cancers. Because prognosis is related to the extent of disease at
diagnosis, as many as 75% of patients with colorectal cancer
might be cured if the disease were detected early enough. The
occult blood test is of great significance in detecting early disease
and potentially reducing mortality associated with colorectal
cancer.-Anthony J. Mastromarino, PhD, Vice President for
Research
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